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Abstract A retrospective study was performed to assess the
outcome of patients with diffuse large B cell lymphoma
(DLBCL) who did not achieve complete response or who
relapsed before and after the use of rituximab. Clinical fea-
tures and outcome of 816 (425M/391 F; median age 63 years)
patients diagnosed from 1991 to 2001 (pre-rituximab era,
N=348) and from 2002 to 2012 (rituximab era, N=468)
in a single institution were evaluated. Five hundred fifty-
three patients achieved complete remission (CR), 57 partial
response (PR), and 206 were refractory with a median
overall survival of 15, 1.5, and 0.4 years, respectively.
Patients receiving rituximab had lower risk of refractori-
ness or relapse. In primarily refractory and PR patients,
there was not a difference in survival depending on
whether patients received or not rituximab-containing
frontline treatment. Early death rate was 11 %, including
3.6 % due to infectious complications. Rituximab did not
modify these figures. In the relapse setting, 5-year survival
from relapse was 25 % for patients who never received
rituximab, 54 % for those who received rituximab only at
relapse, and 48 % for those treated with immunochemotherapy
both as frontline and at relapse. In conclusion, relapsed/
refractory patients with DLBCL show poor prognosis despite
the use of frontline immunochemotherapy. New therapeutic
approaches are needed in this group of patients.
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Introduction
Diffuse large B cell lymphoma (DLBCL) is the commonest
subtype of non-Hodgkin’s lymphoma accounting for approx-
imately 30–50 % of cases [1]. DLBCL shows an aggressive
behavior with a median survival of less than 1 year in untreat-
ed patients. Since the 1970s, the CHOP regimen (cyclophos-
phamide, adriamycin, vincristine, and prednisone) has been
the standard treatment with 50% of complete remissions (CR)
and 30–40 % of long survivors [2]. Prognosis of DLBCL
has considerably improved during the last decade, mainly
due to the addition of rituximab, the first approved anti-
CD20 monoclonal antibody, to chemotherapy (CT), known
as immunochemotherapy. The addition of rituximab to
firstline treatment improved CRs by 15–20 %, 5-year
event-free survival (EFS) from 29 to 47 % in patients 60
to 80 years old and 3-year EFS or progression-free survival
(PFS) from 59 to 79 % in patients aged 18 to 60 [3–9].
More importantly, immunochemotherapy significantly im-
proved overall survival (OS) [3–9]. Therefore, rituximab-
CT (R-CT) became the new standard of care by 2002.
However, despite these notable advancements, there is still
a considerable proportion of patients that are primarily
refractory or experience short-term relapses impairing their
possibilities of survival. For patients with chemosensitive
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disease, the standard treatment for relapsed/refractory
DLBCL cases is salvage CT followed by autologous stem
cell transplantation (ASCT) [10]. Patients who progress
while receiving frontline therapy or those relapsing very
early (the so-called primary chemorefractory patients) are
less likely to respond to salvage treatment and therefore,
have a clearly inferior PFS and OS than late relapses [11, 12].
After the PARMA study, several retrospective analyses have
supported the role of ASCT in primarily chemorefractory
cases [13, 14]. Typical salvage CT regimens are platinum
based plus high-dose cytarabine, ifosfamide or gemcitabine.
Currently, the use of immunochemotherapy at relapse is gen-
eralized, although the evidence to support this fact, particularly
in R-CT refractory patients, is scarce. Moreover, it has been
suggested that the prognosis of relapsed/refractory patients is
worse nowadays than before rituximab [15, 16]. Whether the
outcome of DLBCL patients not reaching CR or who eventu-
ally relapse has changed in the last decade with the use of
frontline immunochemotherapy is still an open question.
In this setting, the aim of the present study was to assess the
clinical features, response to salvage treatment, PFS and OS of
patients with relapsed/refractory DLBCL before and after the
addition of rituximab to firstline therapy in a single institution.
Patients and methods
Patients
Nine hundred eighty-three patients were consecutively diag-
nosed with DLBCL according to theWHO classification [17],
in a single institution between 1991 and 2012. The only
criterion to include patients was the availability of histological
material. Patients with post-transplant lymphoproliferative
disorders (N=9), immunodeficiency-associated (N=95), cen-
tral nervous system (N=39), primary effusion (N=1), and
primarily mediastinal lymphomas (N=37) were excluded.
Thus, 816 patients were the subject of the present study.
Patients were divided in two groups: 348 patients (42.6 %)
diagnosed during the pre-rituximab era (1991–2001) (pre-R)
and 468 patients (57.4 %) during the rituximab period (2002–
2012) (R). The main characteristics of patients are described
in Table 1. The median age of patients was 63 years (range
14–94) and the male/female distribution 425 (52 %)/391
(48 %). Most variables showed no significant differences
through time, but during the last decade, the median age was
higher and the proportion of extranodal involvement lower.
The first cohort of patients received chemotherapy (CT) and
the second one immunochemotherapy (R-CT) unless intoler-
ance or toxicity (N=3). The frontline regimens slightly varied
over time and could be summarized as curative intention
(CHOP or CHOP-like) or palliative intention (COP) depending
on the use or not of adriamycin. The proportion of patients
treated with curative intention was higher in the second cohort
than that in the first one (85 vs 78 %, respectively; P=0.01).
The study was performed according to the guidelines of
the Ethic Committee of the Hospital Clínic of Barcelona.
Informed consent to use the clinical data was obtained in
accordance with the Declaration of Helsinki.
Staging and treatment
The following variables were recorded and analyzed: (i)
demographic data, performance status according to the
Eastern Cooperative Oncology Group (ECOG) scale, presence
of B symptoms (fever, night sweats, weight loss), and bulky
disease (defined as a tumor diameter >7 cm); (ii) hematological
and biochemical parameters: blood cell counts, hemoglobin,
serum lactate dehydrogenase (LDH), and β2-microglobulin
(β2m) levels; (iii) tumor extension data: nodal and extranodal
involvement, number of extranodal involved sites, palpable
splenomegaly or hepatomegaly, bone marrow infiltration and
Ann Arbor Stage; (iv) the International Prognostic Index (IPI)
[18]; (v) treatment; response to treatment, relapse, cause of
death; (vi) appearance of secondary neoplasias.
Response to therapy and outcome
The criteria to assess response were those of Cheson 1999,
based on CT scan. Thus, CR was defined as the total disap-
pearance of tumor masses and disease-related symptoms as
well as the normalization of the initial abnormal test for at least
1 month. CR/unconfirmed (CRu) included a residual lymph
node mass greater than 1.5 cm that regressed more than 75 %
and individual nodes that were previously confluent that
regressed more than 75 %. Partial response (PR) was consid-
ered when tumor mass or organ infiltration decreased by at
least 50 % along with the disappearance of disease-related
symptoms. CR and CRu patients were analyzed together. In
addition, since 2005 when PET scan became available in our
institution, this procedure was used to assess response, and
therefore, patients with residual masses were considered in PR
when PET scan was positive and in CR when PET scan
was negative [19]. Patients not included in these categories
and early deaths were considered nonresponders. Early
death was defined as those patients dying within the
4 months after diagnosis. Disease relapse or progression
was defined as the appearance of new symptoms or signs
of the disease as demonstrated by lymph node biopsy or
other appropriate studies. OS and PFS were calculated
according to standard definitions [19].
Statistical methods
Differences among the subgroups of patients were assessed by
using the Chi-square test (two-tailed), the Student’s t test, or
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nonparametric tests when necessary. The actuarial survival
analysis was performed by the Kaplan and Meier method
and differences assessed by the log-rank test. To evaluate
the prognostic impact of different variables in response to
salvage therapy, PFS, and OS, multivariate analyses were
performed with the stepwise proportional hazards model
(Cox model) [20]. P values <0.05 were considered statis-
tically significant.
Results
Response to frontline treatment and outcome
After therapy, 553 patients (68 %) achieved CR, 57 PR (7 %),
and 206 did not respond (25 %). As expected, the CR rate
was higher in patients treated with R-CT compared to those
receiving CT alone (71 vs 64 %, respectively; P=0.036)
and particularly in patients treated with curative intention
(77 vs 68 %, respectively; P=0.009). In addition, the
proportion of primary refractory cases was significantly
lower in the R-CT subgroup (29 vs 23 %, respectively;
P=0.05), specifically in patients treated with curative inten-
tion (24 vs 15 %, respectively; P=0.009). Those patients
(N=263) who did not achieve CR were older and more
often had poor ECOG performance status, B symptoms,
advanced Ann Arbor stage, bulky disease, extranodal in-
volvement, bone marrow and CNS infiltration, high serum
LDH and β2m, high-risk IPI and received palliative ap-
proach as compared with those achieving CR (P≤0.008 in
all cases).
Median follow-up for surviving patients was 6.5 years
(range 0.02–23.2). One hundred fifty out of 553 patients in
CR eventually relapsed. Five-year PFS was 45.5 % (95 % CI
44.4–46.6 %), with significant differences between the pre-R
and R period (5-year PFS 39 vs 51 %, respectively; P=0.002)
(Table 2). This difference was also observed in patients treated
with curative intention (5-year PFS 45 vs 57 %, respectively;
P=0.002). Four hundred and nineteen patients died during the
follow-up with a 5-year OS of 54 % (95 % CI 50.2–57.2 %),
with a significant difference between pre-R and R eras (5-year
OS 48 vs 59 %, respectively; P=0.004). Once again, the
difference was maintained in patients treated with curative
intention (5-year OS 55 vs 65 %, respectively; P=0.006). A
multivariate analysis showed that in a model of 582 patients,
Table 1 Clinical characteristics
at diagnosis of 816 patients with
diffuse large B cell lymphoma
ECOG Eastern Cooperative
Oncology Group, LDH lactate
dehydrogenase, β2m β2-
microglobulin, BM bone marrow
*P<0.05
All 1991–2001 2002–2012
N (%) N (%) N (%)
Patients 816 (100) 348 (43) 468 (57)
Gender
Male 425 (52) 167 (48) 258 (55)*
Female 391 (48) 181 (52) 210 (45)
Age
≤60 364 (45) 174 (50) 190 (41)*
>60 452 (55) 174 (50) 278 (59)
B symptoms 319 (40) 132 (38) 187 (41)
ECOG performance status
<2 465 (59) 191 (55) 274 (62)
≥2 319 (41) 153 (44) 166 (38)
Bulky disease (>7 cm) 226 (29) 102 (30) 124 (29)
Primarily extranodal 290 (35) 140 (40) 150 (32)*
Extranodal involvement 525 (64) 242 (70) 283 (60)*
BM involvement 126 (16) 65 (19) 61 (13)*
Ann Arbor stage
I–II 380 (47) 175 (51) 205 (45)
III–IV 426 (53) 171 (49) 255 (55)
High serum LDH 395 (52) 181 (55) 214 (50)
High serum β2m 280 (46) 103 (45) 177 (47)
IPI risk group
Low 271 (35) 120 (36) 151 (34)
Low intermediate/high intermediate 326 (42) 127 (38) 199 (45)
High 179 (23) 83 (25) 96 (21)
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IPI (P<0.0001, HR 1.9, 95 % CI 1.7–2.3), use of rituximab
(P<0.0001, HR 0.5, 95 % CI 0.4–0.6) and bulky disease
(P=0.048, HR 1.3, 95 % CI 1.0–1.6) were the most
important variables affecting OS. PFS and OS curves of
the whole series and of those patients treated with curative
intention are shown in Fig. 1. The cause of death was
lymphoma in 83 % of cases which was similar in both
groups. Twenty-seven second neoplasias (3.4 %) were
detected during the follow-up with no significant differences
between the two subgroups.
Salvage treatment in primary chemorefractory patients
Ninety-two out of 206 patients (45 %) who did not reach a
response died within 4 months from diagnosis, including 10
patients who were never treated. These early death rates in
patients receiving CTor R-CTwere 35/348 (10 %) versus 57/
468 (12 %), respectively. Infectious complications were the
ultimate cause of death in 30 cases (3.2 vs 4 % in pre-R and R
era, respectively), irrespective of the possible response of the
disease. One hundred fourteen patients surviving more than
Table 2 Outcome of 816 patients with diffuse large B cell lymphoma
Whole series 1991–2001 2002–2012 P value
N=816 N=348 N=468
Treatment response, N (%) 0.036
CR 553 (68) 222 (64) 331 (71)
PR 57 (7) 26 (7) 31 (7)
No response 206 (25) 100 (29) 106 (23)
PFS at 5 years (%) 45.5 39 51 0.002
OS at 5 years (%) 53.7 48 59 0.004
Relapse after CR, N (%) 150 (27) 81 (36) 69 (21) <0.0001
Survival from relapse at 5 years (%) 29 29 35 NS
Relapse ≤2 years from CR (%) 20 21 19 NS
Relapse >2 years from CR (%) 46 44 48 NS
CR complete response, PR partial response, PFS progression-free survival, OS overall survival
Fig. 1 Outcome of the whole series of patients with diffuse large B cell
lymphoma (a) and of those treated with curative intention (b). Overall
survival (OS) and progression-free survival (PFS) of the subgroups
(a1, b1). PFS according to the year of diagnosis (before and after
December 2001) (a2, b2). OS according to the year of diagnosis
(before and after December 2001) (a3, b3)
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4 months were primary refractory to treatment; the median OS
of this group was 0.75 years (Fig. 2a). Sixty-one of these
patients (31 pre-R; 30 R) received only palliative measures
mainly due to age and/or poor ECOG performance status, and
all of them died between 4 and 44 months from diagnosis.
Salvage treatment was administered to 53 patients (34 and 19
in the pre-R and R era, respectively). In the pre-R era, only one
patient achieved CR (3 %) and three PR (9 %) whereas in the
R era, three patients achieved CR (16 %) and five PR (26 %)
(P=0.027). One patient in PR in the pre-R era received allo-
geneic stem cell transplantation (Allo-SCT). This patient died
in CR at 7.2 years after transplant due to esophagus carcino-
ma. In the R era, three patients received an ASCT and one an
Allo-SCT. The only patient in the pre-R era who achieved CR
died due to a stroke 14 years from the assessment of response.
Three patients in the R era were long survivors. Overall, the
median survival after salvage therapy of those patients treated
with curative intention was 0.46 years (0.39 years in pre-R era
vs 0.64 years in R era; P=0.044) (Fig. 2b). Responses and
survival after salvage treatment are summarized in Table 3.
Salvage treatment in patients in PR
Fifty-seven patients were in PR after induction therapy,
26/348 (7.5 %) treated with CT, and 31/468 (7 %) with
R-CT. When restricted to curative treatment, the figures
were 22/271 (8.1 %) and 29/397 (7.3 %). Fifteen of the
57 patients (6 pre-R; 9 R) received only palliative mea-
sures, whereas 42 (20 pre-R; 22 R) received ESHAP
salvage therapy (etoposide, methylprednisolone, high-dose
cytarabine, and cisplatin). Only two patients in the pre-R
era received rituximab as part of salvage therapy, whereas
all the cases in the R era were treated with R-ESHAP. CR rates
were 25 % (5 out of 20) and 50 % (11 out of 22) in the pre-R
and R era, respectively (P=0.09). ASCTwas performed in four
pre-R and nine R patients. Long survival was 11.5 % (N=3)
and 35 % (N=11), respectively (P=0.03). Overall, the median
survival after salvage treatment was 1 year, with a 5-year
survival from rescue therapy of 19 vs 32 % for patients in the
pre-R and R eras (Fig. 3a). Regarding patients treated with
curative intention, the 5-year survival after salvage treatment
was 26 vs 38 % (Fig. 3b and Table 3). Among four patients
who underwent ASCT in the pre-R era, two achieved CR and
two died early after ASCT due to cardiogenic shock and
infection. One patient in CR died shortly afterward of disease
progression. In the R era, six out of nine patients achieved CR,
three died of disease progression, and two relapsed and were
treated with a reduced intensity Allo-SCT. One of them died
due to infectious complication, and the other patient is alive
after 10 years.
Salvage treatment in relapsed patients
One hundred and fifty out of 553 patients (27.1 %) in CR
eventually relapsed (Table 2). Such proportion was 36 and
21 % during the pre-R and R era, respectively (P<0.0001). In
the 70 patients in whom a new biopsy was performed, the
histology at relapse corresponded to DLBCL in 95 % of cases
and to a downgrade relapse in 5 % (all follicular lymphoma).
Relapse was primarily extranodal in 58 cases. No differences
in the localization relapse or histology were observed between
the pre-R and R eras. During the last decade, the CR duration
(time from CR achievement to relapse) has been significantly
longer than that in the pre-R era (median time 0.75 vs
1.5 years; P=0.027). Finally, more relapses occurred in
older patients (>70 years), namely, 17 % pre-R vs 39 % R
era (P=0.003).
Salvage treatment consisted of CT or R-CT followed by
ASCT for those patients <65–70 years of age, good perfor-
mance status and achieving PR or CR after rescue. This
Fig. 2 Survival from salvage treatment of frontline chemorefractory patients diagnosed before or after December 2001. a All patients; b only patients
with curative intention to salvage treatment
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intensive approach was performed in 82 % of pre-R patients
and 56% of R patients. This differencewas because the second
group was older. On the other hand, 11 of 76 patients initially
treated only with CT received rituximab at relapse, whereas all
patients treated in the R era received rituximab at relapse.
CR rates after salvage therapy were 42 versus 39 % in the
pre-R and R era, respectively. In those patients treated with
curative intention, CR rates were 51 versus 59 % (Table 3).
Median survival from relapse (SFR) was 1.12 years, with a
29 % pre-R versus 28 % R 5-year SFR in pre-R and R eras
(Fig. 4a). Median SFR of patients treated with curative inten-
tion was 2 years, whereas 5-year SFR was 33 versus 42 % in
the pre-R and R eras, respectively (Fig. 4b). Variables at
relapse predicting shorter SFR were older age (5-year SFR
of 39 versus 22% for patients <60 and ≥60 years, respectively,
P=0.04) and CNS relapse (5-year SFR of 37 and 18 %
patients with or without CNS involvement, respectively,
P=0.02). A trend to shorter SFR was observed in those
patients relapsing during the first 2 years after CR achieve-
ment (5-year SFR of 20 versus 46 % for patients relapsing
≤2 years or later, P=0.07). SFR is shown in Fig. 5 according
to the use of rituximab in front line and at relapse. Five-year
SFR was 25, 54, and 48 % for patients who never received
rituximab, those who received the drug only at relapse and
those treated with rituximab both in front line and rescue
regimen, respectively (P=0.007). Such differences were
maintained in patients treated with curative intention
(Fig. 5b). A multivariate analysis showed that in a model
of 69 patients, age at relapse >70 years (P=0.023, HR
2.1, 95 % CI 1.1–3.9) and CNS involvement (P=0.04,
HR 2.1, 95 % CI 1.0–4.4) were the most important
variables to predict SFR.
Discussion
Since the 1970s, the treatment of patients with DLBCL has
been based on CT. The addition of rituximab to CT dramati-
cally improved the outcome of these patients, as demonstrated
Table 3 Outcome of 668 patients with diffuse large B cell lymphoma with chemorefractory disease, partial remission (PR), or relapse, treated with
curative intention













Response to salvage treatment, N (%) 1 (3) 3 (17) 5 (28) 11 (50) 29 (51) 20 (59)
CR 3 (9) 5 (26) 4 (22) 3 (14) 6 (10) 5 (15)
PR
No response
30 (88) 11 (58) 9 (50) 8 (36) 22 (39) 9 (26)
ASCT (%) 3 (9) 4 (21) 4 (22) 9 (41) 21 (37) 9 (26)
5-year survival from progression (%) 6 15* 26 38 33 42
CR complete response, PR partial response, ASCT autologous stem cell transplantation
*P<0.05
Fig. 3 Survival from salvage treatment of patients in partial remission after frontline therapy diagnosed before or after December 2001. aAll patients; b
only patients with curative intention to salvage treatment
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in clinical trials and in retrospective population-based studies
[3–9]. Thus, immunochemotherapy is currently the gold stan-
dard treatment for any CD20-positive DLBCL [3]. Despite
this advance, a considerable number of patients will experi-
ence early failure, partial response, or relapse after initial
rituximab-CT (R-CT). Nowadays, the outcome of relapsed/
refractory (R/R) patients is still poor. Some evidence suggests
that patients treated with R-CT could be more resistant to
salvage therapy than before the use of rituximab. In this setting
and in order to highlight the challenges faced between the pre-
rituximab era and the current immunochemotherapy, the aim
of our study was to evaluate the characteristics and outcome of
those patients with R/R DLBCL after frontline treatment in a
single institution. Published data concerning salvage treatment
is most often based on highly selected series of patients in
whom intensive treatment is possible [4, 6, 10–12, 21–25].
Such cases are not representative of the entire population of
patients who fail to initial therapy. An analysis of an
unselected series of nonresponders, as herein done, can offer
a more realistic view of the efficacy of salvage treatment and
the real outcome in the general population.
Patients dying during induction treatment constitute a par-
ticular category of nonresponders. In the present study, 92
patients (11 % of the overall series and 45 % of nonre-
sponders) died during the induction period. It is often difficult
to distinguish between toxic death and disease progression as
causes of death. In our series, 3.7 % of patients died due
to infectious complications. No differences were observed
between patients receiving CT or R-CT. This mortality rate
is similar to that reported in the literature [3, 5, 26]. After
excluding early deaths, primary refractory patients were
considered as a different category which accounted for
14 % of the present series. More than half of them
received only palliative measures mainly due to older age
and/or poor performance status. All of them died within the
next 3 years. Only 9 % of rescued patients achieved CR,
although this proportion has improved in the last decade.
These data apparently contrast with those reported in the
Fig. 4 Survival from relapse diagnosed before or after December 2001. a All patients; b only patients with curative intention to salvage treatment
Fig. 5 Survival from relapse according to rituximab treatment at
diagnosis or relapse. CT→R-CT chemotherapy at diagnosis and
immunochemotherapy at relapse; R-CT→R-CT immunochemotherapy
both at diagnosis and at relapse; CT→CT chemotherapy both at
diagnosis and at relapse; a all cohort; b only patients treated with
curative intention at relapse
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pre-R era with overall response rates between 39 and 69 %
including CR rates of 18–48 % [27–30]. However, in those
series, the proportion of primary refractory patients was very
low. In fact, our results in the R era are similar to those
reported in recent studies with an overall response of
23–33 % and a CR of 6–8 % [11, 31]. These differences
could be related to the definition of primary refractory
disease and the selection of patients. Thus, some series
included patients in PR and refractory as a whole. Our
definition of refractory disease was strict and included
only patients with stable or progressive disease. In sum-
mary, in our study, less than 10 % of the refractory
patients responded to salvage treatment and were candidate
to an eventual intensification. Therefore, it is clear that all
refractory patients should be considered for clinical trials
with new drugs and novel mechanisms of action.
In contrast to other studies, patients in PR after frontline
treatment were grouped separately. The definition of PR can
be a problematic one. Nowadays, thanks to PET scan, it is
easier to define PR and to distinguish this situation from CRu
[19]. In our series, the number of patients in PR could have
been overestimated before the PET scan availability. Since
then, patients with residual masses were considered in PR
when PET scan was positive and CR when PET scan was
negative. Salvage treatment followed by ASCT is the standard
of care for patients in PR. However, this approach is based in
old retrospective studies, and there is some controversy since
prospective trial data supporting the use of ASCT is lacking,
particularly in the R-CT era [13, 14, 23, 32]. In the current
study, PR patients represented 7 % of all series and showed a
considerably better response to salvage treatment and out-
come than primary refractory patients. When comparing data
between the pre-R and R era, a slight improvement in CR rate
and outcome after rescue did not reach statistical significance
probably due to the low number of patients. In addition, a
higher proportion of patients in this category may benefit from
ASCT [15, 16, 25, 31, 33–36]. In this regard, it is of note that
15 of the 75 patients (20 %) could receive only palliative
measures due to their older age or poor performance status.
Conversely, despite the relatively high CR rate, long-term
disease-free survival is rather modest with less than one third
of patients being cured [25, 26, 31].
The last category is that of patients relapsing after having
achieved CR. In recent studies, data indicates that the addition
of rituximab to CT implies a substantial reduction of relapse
with rates ranging from 20 to 35 % [8, 21, 24]. We have
corroborated this finding with relapsing rates of 36 versus
21 % for patients receiving CT or R-CT, respectively. After
the PARMA trial, the standard approach for relapsed patients
(if eligible) is salvage therapy followed by ASCT. Fifty-
three percent of OS is expected in sensitive patients [10].
The only prospective randomized trial of patients with
DLBCL in first relapse or primary refractory in the rituximab
era is the CORAL, in which 396 patients were randomized in
2 groups of salvage treatment: R-ICE (rituximab, ifosfamide,
carboplatin, etoposide) versus R-DHAP (rituximab, dexa-
methasone, high-dose citarabine, cisplatinum) followed by
ASCT in responders. No difference in outcome between the
groups was recorded, and a 10 % improvement in terms of
outcome was observed with respect to the pre-R era [15,
34–36]. However, Gisselbrecht et al. published that chemo-
therapy sensitivity before ASCT positively affected response
rates, whereas the use of rituximab in first-line treatment had
negative effect in those patients relapsing within 12 months
after initial CR [15]. The role of rituximab in the second-line
setting in refractory patients or in patients whose lymphoma
progressed on R-CHOP is also unclear. Current information
about the utility of rituximab as part of salvage treatment
comes from retrospective analyses [6]. Unfortunately, it does
not seem likely that prospective studies are planned to assess
this issue. The addition of rituximab to second-line CT follow-
ed by ASCT has significantly improved PFS in patients not
previously exposed to rituximab [25]. We have also observed
that rituximab-naïve patients responded better to salvage treat-
ment followed by ASCT compared to those patients treated
both times with rituximab-containing regimens and to those
who never received rituximab. This latter group had the worst
prognosis. CR duration has been considered one of the most
important prognostic factors for outcome in relapsed patients
[37]. Interestingly, in our series, patients relapsing after R-CT
showed a longer CR duration than those relapsing after CT
(1.5 vs 0.7 years). This could be in part the reason why the
short duration of CR had a modest impact on survival in the
present series.
Based on the PARMA trial, ASCT is the standard of care in
R/R patients with DLBCL responding to salvage treatment.
However, no other randomized information is available, par-
ticularly in the R era. We must be cautious with results from
clinical trials as from other published data concerning salvage
treatment approaches since there are most often based on
highly selected series of patients in whom intensive treatment
is possible [4, 6, 10–12, 21–25]. In fact, the median age of
those series is low. Most likely such patients who fail initial
therapy are not representative of the entire population. In the
present series which includes the whole population of R/R
patients, it is of note that only a minority of those could benefit
from intensified treatments. Therefore, the proportion of cases
transplanted was 22, 23, and 9 % for relapsed, PR, and
refractory patients, respectively. Moreover, the use of rituxi-
mab does not seem to have changed this situation.
Prognosis of DLBCL has considerably improved during
the last 10 years. However, an important proportion of patients
are not yet cured, and the treatment of relapses remains
unsatisfactory as shown in the present series. Achieving a
sustained CR after first-line therapy is an essential goal. A
better biological understanding of early relapses and primarily
810 Ann Hematol (2015) 94:803–812
refractory lymphomas is needed, as well as the development
of new drugs with different mechanisms of action for R/R
patients.
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